1
|
Stoner MCD, Smith L, Ming K, Mancuso N, Patani H, Sukhija-Cohen A, Granados Y, Wagner D, Johnson MO, Napierala S, Neilands TB, Saberi P. Results from a pilot study of an automated directly observed therapy intervention using artificial intelligence with conditional economic incentives among young adults with HIV. J Acquir Immune Defic Syndr 2024:00126334-990000000-00381. [PMID: 38363868 DOI: 10.1097/qai.0000000000003397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2023] [Accepted: 01/23/2024] [Indexed: 02/18/2024]
Abstract
BACKGROUND Despite improvements in antiretroviral therapy (ART) availability, suboptimal adherence is common among youth with HIV (YWH) and can increase drug resistance and poor clinical outcomes. Our study examined an innovative mobile app-based intervention that used automated directly observed therapy (aDOT) using artificial intelligence, along with conditional economic incentives (CEIs) to improve ART adherence and enhance viral suppression among YWH. SETTING We conducted a pilot study of the aDOT-CEI intervention, informed by the operant framework of Key Principles in Contingency Management Implementation, to improve ART adherence among YWH (18-29) in California and Florida who had an unsuppressed HIV viral load. METHODS We recruited 28 virally unsuppressed YWH from AIDS Healthcare Foundation (AHF) clinics, who used the aDOT platform for 3 months. Study outcomes included feasibility and acceptability, self-reported ART adherence, and HIV viral load. RESULTS Participants reported high satisfaction with the app (91%), and 82% said that it helped them take their medication. Comfort with the security and privacy of the app was moderate (55%), and 59% indicated the incentives helped improve daily adherence. CONCLUSION Acceptability and feasibility of the aDOT-CEI intervention were high with potential to improve viral suppression, although some a priori metrics were not met. Pilot results suggest refinements which may improve intervention outcomes, including increased incentive amounts, provision of additional information, and reassurance about app privacy and security. Additional research is recommended to test the efficacy of the aDOT-CEI intervention to improve viral suppression in a larger sample.
Collapse
Affiliation(s)
- Marie C D Stoner
- Women's Global Health Imperative, RTI International, Berkeley, CA, USA
| | - Louis Smith
- Department of Medicine and University of California, San Francisco, San Francisco, California, USA
| | - Kristin Ming
- Department of Medicine and University of California, San Francisco, San Francisco, California, USA
| | - Noah Mancuso
- Women's Global Health Imperative, RTI International, Atlanta, GA, USA
| | - Henna Patani
- AIDS Healthcare Foundation, Los Angeles, CA, USA
| | | | | | - Danielle Wagner
- Women's Global Health Imperative, RTI International, Berkeley, CA, USA
| | - Mallory O Johnson
- Department of Medicine and University of California, San Francisco, San Francisco, California, USA
| | - Sue Napierala
- Women's Global Health Imperative, RTI International, Berkeley, CA, USA
| | - Torsten B Neilands
- Department of Medicine and University of California, San Francisco, San Francisco, California, USA
| | - Parya Saberi
- Department of Medicine and University of California, San Francisco, San Francisco, California, USA
| |
Collapse
|
2
|
Stoner MCD, Ming K, Wagner D, Smith L, Patani H, Sukhija-Cohen A, Johnson MO, Napierala S, Neilands TB, Saberi P. Youth Ending the HIV Epidemic (YEHE): Protocol for a pilot of an automated directly observed therapy intervention with conditional economic incentives among young adults with HIV. PLoS One 2023; 18:e0289919. [PMID: 38134037 PMCID: PMC10745168 DOI: 10.1371/journal.pone.0289919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2023] [Accepted: 07/13/2023] [Indexed: 12/24/2023] Open
Abstract
BACKGROUND Young adults have a disproportionately high rate of HIV infection, high rates of attrition at all stages of the HIV care continuum, and an elevated probability of disease progression and transmission. Tracking and monitoring objective measures of antiretroviral therapy (ART) adherence in real time is critical to bolster the accuracy of research data, support adherence, and improve clinical outcomes. However, adherence monitoring often relies on self-reported and retrospective data or requires additional effort from providers to understand individual adherence patterns. In this study, we will monitor medication-taking using a real-time objective measure of adherence that does not rely on self-report or healthcare providers for measurement. METHODS The Youth Ending the HIV Epidemic (YEHE) study will pilot a novel automated directly observed therapy-conditional economic incentive (aDOT-CEI) intervention to improve ART adherence among youth with HIV (YWH) in California and Florida who have an unsuppressed HIV viral load. The aDOT app uses facial recognition to record adherence each day, and then economic incentives are given based on a participant's confirmed adherence. We will enroll participants in a 3-month pilot study to assess the feasibility and acceptability of the aDOT-CEI intervention using predefined metrics. During and after the trial, a subsample of the pilot participants and staff/providers from participating AIDS Healthcare Foundation (AHF) clinics will participate in individual in-depth interviews to explore intervention and implementation facilitators and barriers. DISCUSSION YEHE will provide data on the use of an aDOT-CEI intervention to improve adherence among YWH who are not virologically suppressed. The YEHE study will document the feasibility and acceptability and will explore preliminary data to inform a trial to test the efficacy of aDOT-CEI. This intervention has the potential to effectively improve ART adherence and virologic suppression among a key population experiencing health disparities. TRIAL REGISTRATION The trial registration number is NCT05789875.
Collapse
Affiliation(s)
- Marie C. D. Stoner
- Women’s Global Health Imperative, RTI International, Berkeley, California, United States of America
| | - Kristin Ming
- Center for AIDS Prevention Studies, University of California San Francisco, San Francisco, California, United States of America
| | - Danielle Wagner
- Women’s Global Health Imperative, RTI International, Berkeley, California, United States of America
| | - Louis Smith
- Center for AIDS Prevention Studies, University of California San Francisco, San Francisco, California, United States of America
| | - Henna Patani
- AIDS Healthcare Foundation, Los Angeles, California, United States of America
| | - Adam Sukhija-Cohen
- AIDS Healthcare Foundation, Los Angeles, California, United States of America
| | - Mallory O. Johnson
- Center for AIDS Prevention Studies, University of California San Francisco, San Francisco, California, United States of America
| | - Sue Napierala
- Women’s Global Health Imperative, RTI International, Berkeley, California, United States of America
| | - Torsten B. Neilands
- Center for AIDS Prevention Studies, University of California San Francisco, San Francisco, California, United States of America
| | - Parya Saberi
- Center for AIDS Prevention Studies, University of California San Francisco, San Francisco, California, United States of America
| |
Collapse
|
3
|
Saberi P, Stoner MCD, McCuistian CL, Balaban C, Ming K, Wagner D, Chakraborty B, Smith L, Sukhija-Cohen A, Neilands TB, Gruber VA, Johnson MO. iVY: protocol for a randomised clinical trial to test the effect of a technology-based intervention to improve virological suppression among young adults with HIV in the USA. BMJ Open 2023; 13:e077676. [PMID: 37802624 PMCID: PMC10565330 DOI: 10.1136/bmjopen-2023-077676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Accepted: 09/19/2023] [Indexed: 10/10/2023] Open
Abstract
INTRODUCTION Young adults with HIV (YWH) experience worse clinical outcomes than adults and have high rates of substance use (SU) and mental illness that impact their engagement in care and adherence to antiretroviral therapy (ART). The intervention for Virologic Suppression in Youth (iVY) aims to address treatment engagement/adherence, mental health (MH) and SU in a tailored manner using a differentiated care approach that is youth friendly. Findings will provide information about the impact of iVY on HIV virological suppression, MH and SU among YWH who are disproportionately impacted by HIV and at elevated risk for poor health outcomes. METHODS AND ANALYSIS The iVY study will test the effect of a technology-based intervention with differing levels of resource requirements (ie, financial and personnel time) in a randomised clinical trial with an adaptive treatment strategy among 200 YWH (18-29 years old). The primary outcome is HIV virological suppression measured via dried blood spot. This piloted and protocolised intervention combines: (1) brief weekly sessions with a counsellor via a video-chat platform (video-counselling) to discuss MH, SU, HIV care engagement/adherence and other barriers to care; and (2) a mobile health app to address barriers such as ART forgetfulness, and social isolation. iVY has the potential to address important, distinct and changing barriers to HIV care engagement (eg, MH, SU) to increase virological suppression among YWH at elevated risk for poor health outcomes. ETHICS AND DISSEMINATION This study and its protocols have been approved by the University of California, San Francisco Institutional Review Board. Study staff will work with a Youth Advisory Panel to disseminate results to YWH, participants and the academic community. TRIAL REGISTRATION NUMBER NCT05877729.
Collapse
Affiliation(s)
- Parya Saberi
- Center for AIDS Prevention Studies, University of California San Francisco, San Francisco, California, USA
| | - Marie C D Stoner
- Women's Global Health Imperative, RTI International, Berkeley, California, USA
| | - Caravella L McCuistian
- Department of Psychiatry and Behavioral Sciences, University of California San Francisco, San Francisco, CA, USA
| | - Celeste Balaban
- Center for AIDS Prevention Studies, University of California San Francisco, San Francisco, California, USA
| | - Kristin Ming
- Center for AIDS Prevention Studies, University of California San Francisco, San Francisco, California, USA
| | - Danielle Wagner
- Women's Global Health Imperative, RTI International, Berkeley, California, USA
| | - Bibhas Chakraborty
- Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, NC, USA
- Centre for Quantitative Medicine and Program in Health Services and Systems Research, Duke-NUS Medical School, Singapore
- Department of Statistics and Data Science, National University of Singapore, Singapore
| | - Louis Smith
- Center for AIDS Prevention Studies, University of California San Francisco, San Francisco, California, USA
| | | | - Torsten B Neilands
- Center for AIDS Prevention Studies, University of California San Francisco, San Francisco, California, USA
| | - Valerie A Gruber
- Department of Psychiatry and Behavioral Sciences, University of California San Francisco, San Francisco, CA, USA
| | - Mallory O Johnson
- Center for AIDS Prevention Studies, University of California San Francisco, San Francisco, California, USA
| |
Collapse
|
4
|
Maragh-Bass AC, Stoner MCD, Castellanos-Usigli A, Agarwal H, Katz AWK, Patani H, Sukhija-Cohen A, Campbell L, Arreola S, Saberi P. New preexposure prophylaxis options need updated counseling approaches: reframing 'risk' in HIV prevention counseling for young sexual and gender minorities of color. AIDS 2023; 37:1361-1366. [PMID: 37070546 DOI: 10.1097/qad.0000000000003563] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/19/2023]
Affiliation(s)
- Allysha C Maragh-Bass
- Behavioral, Epidemiological, Clinical Sciences Division, FHI 360
- Duke Global Health Institute, Duke University, Durham, North Carolina
- Center for AIDS Prevention Studies, University of California
| | | | - Antón Castellanos-Usigli
- ACU Innovations & Consulting, New York, New York
- TH Chan School of Public Health, Harvard University, Boston, Massachusetts
| | - Harsh Agarwal
- Behavioral, Epidemiological, Clinical Sciences Division, FHI 360
| | | | | | | | | | | | - Parya Saberi
- Center for AIDS Prevention Studies, University of California
| |
Collapse
|
5
|
Allan-Blitz LT, Carragher K, Sukhija-Cohen A, Ritchie P, Scott H, Li H, Klausner JD. Laboratory validation and clinical performance of a saliva-based test for monkeypox virus. J Med Virol 2023; 95:e28191. [PMID: 36183189 PMCID: PMC10091791 DOI: 10.1002/jmv.28191] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2022] [Revised: 09/13/2022] [Accepted: 09/27/2022] [Indexed: 01/11/2023]
Abstract
Improved diagnostic tests and accessibility are essential for controlling the outbreak of monkeypox. We describe a saliva-based polymerase chain reaction (PCR) assay for monkeypox virus, in vitro test performance, and clinical implementation of that assay in Los Angeles, San Francisco, and Palm Springs, CA. Finally, using prespecified search terms, we conducted a systematic rapid review of PubMed and Web of Science online databases of studies reporting the performance of oral pharyngeal or saliva-based tests for the monkeypox virus. The assay showed in silico inclusivity of 100% for 97 strains of monkeypox virus, with an analytic sensitivity of 250 copies/ml, and 100% agreement compared to known positive and negative specimens. Clinical testing identified 22 cases of monkeypox among 132 individuals (16.7%), of which 16 (72.7%) reported symptoms, 4 (18.2%) without a rash at the time of testing. Of an additional 18 patients with positive lesion tests, 16 (88.9%) had positive saliva tests. Our systematic review identified six studies; 100% of tests on oropharyngeal specimens from 23 patients agreed with the PCR test result of a lesion. Saliva-based PCR tests are potential tools for case identification, and further evaluation of the performance of such tests is warranted.
Collapse
Affiliation(s)
- Lao-Tzu Allan-Blitz
- Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Kevin Carragher
- Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, California, Los Angeles, USA
| | - Adam Sukhija-Cohen
- AIDS Healthcare Foundation, Public Health Division, Los Angeles, California, USA
| | | | - Hyman Scott
- San Francisco Department of Public Health, San Francisco, California, USA
| | - Hong Li
- Flow Health, Los Angeles, California, USA
| | - Jeffrey D Klausner
- Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, California, Los Angeles, USA
| |
Collapse
|
6
|
Stoner MC, Maragh-Bass A, Sukhija-Cohen A, Saberi P. Digital directly observed therapy to monitor adherence to medications: a scoping review. HIV Res Clin Pract 2022; 23:47-60. [PMID: 35904111 PMCID: PMC9554236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Background: Technology-based directly observed therapy (DOT) is more cost-effective and efficient compared with in-person monitoring visits for medication adherence. While some evidence shows these technologies are feasible and acceptable, there is limited evidence collating information across medical conditions or in the context of HIV prevention, care, and treatment.Objectives: We conducted a scoping review to understand the current evidence on the acceptability, feasibility, and efficacy of digital DOT to improve medication adherence and, specifically, to determine if digital DOT had been used to improve adherence for HIV prevention, care, and treatmentMethods: We searched the electronic databases PubMed, Embase, and the Web of Science in January 2021 for any published studies with terms related to digital technologies and DOT. We included peer-reviewed studies in any population, from any country, for any outcome, and excluded conference abstracts. We included three types of digital DOT interventions: synchronous DOT, asynchronous DOT, and automated DOT. We provide an assessment of the current evidence, gaps in literature, and opportunities for intervention development regarding the use digital DOT to improve antiretroviral therapy (ART) adherence, specifically in the field of HIV.Results: We identified 28 studies that examined digital DOT. All studies found digital DOT to be acceptable and feasible. Patients using digital DOT had higher rates of treatment completion, observed doses, and adherence compared with in-person DOT, although data were limited on adherence. Only one study examined HIV prevention, and none examined ART adherence for HIV treatment.Conclusions: Digital DOT is acceptable and feasible but has not been used to remotely monitor and support ART adherence for people living with HIV.
Collapse
Affiliation(s)
- Marie C.D. Stoner
- Women’s Global Health Imperative, RTI International, Berkeley, CA, USA
| | - Allysha Maragh-Bass
- Behavioral, Epidemiological, and Clinical Sciences Division, HI 360, Durham, NC, USA,Duke Global Health Institute, Duke University, Durham, NC, USA
| | | | - Parya Saberi
- Center for AIDS Prevention Studies, University of California San Francisco, San Francisco, CA, USA
| |
Collapse
|
7
|
Patani H, Sukhija-Cohen A, Klausner JD, Engeran W, Weinstein M. Disseminated gonococcal infection: a potential marker of failing sexually transmitted infection control and prevention services. Sex Transm Infect 2021; 98:233. [PMID: 34315805 PMCID: PMC9016259 DOI: 10.1136/sextrans-2021-055149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2021] [Accepted: 06/27/2021] [Indexed: 11/15/2022] Open
Affiliation(s)
- Henna Patani
- Public Health Division, AIDS Healthcare Foundation, Los Angeles, California, USA
| | - Adam Sukhija-Cohen
- Public Health Division, AIDS Healthcare Foundation, Los Angeles, California, USA
| | - Jeffrey D Klausner
- Preventive Medicine, University of Southern California, Los Angeles, California, USA
| | - Whitney Engeran
- Public Health Division, AIDS Healthcare Foundation, Los Angeles, California, USA
| | - Michael Weinstein
- Public Health Division, AIDS Healthcare Foundation, Los Angeles, California, USA
| |
Collapse
|
8
|
Jatt LP, Gandhi MM, Guo R, Sukhija-Cohen A, Bhattacharya D, Tseng CH, Chew KW. Barriers to hepatitis C direct-acting antiviral therapy among HIV/hepatitis C virus-coinfected persons. J Gastroenterol Hepatol 2021; 36:1095-1102. [PMID: 32840904 PMCID: PMC7904967 DOI: 10.1111/jgh.15228] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/02/2020] [Revised: 08/11/2020] [Accepted: 08/13/2020] [Indexed: 12/13/2022]
Abstract
BACKGROUND AND AIM Direct-acting antivirals (DAAs) have increased hepatitis C virus (HCV) treatment opportunities for vulnerable HIV/HCV coinfected persons. The aim of this study was to identify the frequency of and potential barriers to DAA prescription in HIV/HCV patients during the first few years of DAA availability in the United States. METHODS The AIDS Healthcare Foundation electronic medical record system was queried to identify all HCV viremic HIV-infected patients in care at AIDS Healthcare Foundation Healthcare centers in January 2015-August 2017 and compare characteristics by receipt of a DAA prescription. Multivariate logistic regression analyses were conducted to examine factors associated with DAA prescription. RESULTS Of 826 eligible patients, 355 (43%) were prescribed a DAA; among those not prescribed a DAA, 301 (64%) had well-controlled HIV (HIV RNA ≤ 200 copies per mL). In multivariate logistic regression analysis, patients with a history of substance use (odds ratio [OR], 0.51 [95% confidence interval 0.35-0.73]) or on select HIV antiretroviral regimens were less likely to be prescribed a DAA. Those who had well-controlled HIV (OR, 5.03 [3.06-8.27]), CD4 + T cell count >200 cells per mm3 (OR, 1.85 [1.04-3.30]), estimated glomerular filtration rate >60 mL/min/1.73 m2 (OR, 3.32 [1.08-10.15]), or established care prior to January 2015 (OR, 1.57 [1.08-2.29] were more likely to be prescribed a DAA. CONCLUSIONS In addition to lack of HIV suppression, select antiretroviral regimens, substance use, and kidney disease appeared to limit DAA prescription in the early interferon-free DAA era. Many were not prescribed DAAs despite HIV suppression. Further research is needed to determine if the observed associations persist today.
Collapse
Affiliation(s)
- Lauren P Jatt
- David Geffen School of Medicine, UCLA, Los Angeles, California, USA
| | - Malini M Gandhi
- Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California, USA
| | - Rong Guo
- Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, UCLA, Los Angeles, California, USA
| | - Adam Sukhija-Cohen
- Public Health Division, AIDS Healthcare Foundation, Los Angeles, California, USA
| | - Debika Bhattacharya
- Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California, USA
| | - Chi-Hong Tseng
- Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, UCLA, Los Angeles, California, USA
| | - Kara W Chew
- Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California, USA
| |
Collapse
|
9
|
Van Der Pol B, Taylor SN, Mena L, Lebed J, McNeil CJ, Crane L, Ermel A, Sukhija-Cohen A, Gaydos CA. Evaluation of the Performance of a Point-of-Care Test for Chlamydia and Gonorrhea. JAMA Netw Open 2020; 3:e204819. [PMID: 32407506 PMCID: PMC7225902 DOI: 10.1001/jamanetworkopen.2020.4819] [Citation(s) in RCA: 36] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
IMPORTANCE Rates of chlamydial and gonococcal infection continue to increase in the United States, as do the associated costs of untreated infections. Improved diagnostic technologies that support testing and treating in 1 clinical visit are critical to advancing efforts to control the rates of chlamydial and gonococcal infection. OBJECTIVE To evaluate the clinical performance of a point-of-care (POC) molecular diagnostic assay for the detection of chlamydia and gonorrhea. DESIGN, SETTING, AND PARTICIPANTS A noninterventional, cross-sectional clinical study was conducted from September 18, 2018, through March 13, 2019, at sexually transmitted infection (STI), HIV, family planning, and obstetrics and gynecology clinics where STI screening is routine, using a convenience sample and comparing commercially available assays with a new 30-minute POC assay. Patients included were those eligible for STI screening or diagnostic testing who had not taken antibiotics effective against chlamydia or gonorrhea within the previous 28 days. Four vaginal swab samples were collected from women and a first-catch urine sample was obtained from men. MAIN OUTCOMES AND MEASURES A composite infection status was used to classify participants as infected if 2 or more comparator results were positive, as not infected if 2 or more comparator samples were negative, and as unevaluable if 1 result was invalid and the other 2 results did not agree with each other. RESULTS Swab samples from 1523 women (median age, 27 years [interquartile range, 17-37 years]), 817 (53.6%) of whom presented with symptoms, and 922 men (median age, 29 years [interquartile range, 17-41 years]), 308 (33.4%) of whom were symptomatic, were tested. For chlamydia, sensitivity of the new POC assay was 96.1% (95% CI, 91.2%-98.3%) for women and 92.5% (95% CI, 86.4%-96.0%) for men. For gonorrhea, sensitivity estimates were 100.0% (95% CI, 92.1%-100.0%) for women and 97.3% (95% CI, 90.7%-99.3%) for men. For chlamydia, specificity of the new POC assay was 99.1% (95% CI, 98.4%-99.5%) for women and 99.3% (95% CI, 98.4%-99.7%) for men. For gonorrhea, specificity estimates were 99.9% (95% CI, 99.5%-100%) for women and 100% (95% CI, 95.5%-100%) for men. Non-laboratory-trained personnel performed 94.8% of all tests (2318 of 2445) during the study. CONCLUSIONS AND RELEVANCE This study suggests that self-obtained vaginal swab samples were associated with performance equivalent to laboratory-based molecular diagnostics, which can support use of this POC assay in many settings. The availability of an easy-to-use, rapid (30-minute) molecular test for accurate detection of chlamydia and gonorrhea has the power to facilitate testing and treatment in a single patient visit for these STIs.
Collapse
Affiliation(s)
- Barbara Van Der Pol
- Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham
| | - Stephanie N. Taylor
- Department of Medicine, Louisiana State University Health Sciences Center, New Orleans
| | - Leandro Mena
- Department of Medicine, University of Mississippi Medical Center, Jackson
| | - Joel Lebed
- Planned Parenthood of Southern Pennsylvania, Philadelphia
| | - Candice Joy McNeil
- Department of Medicine, Wake Forest University Health Sciences, Winston-Salem, North Carolina
| | | | - Aaron Ermel
- Department of Medicine, Indiana University School of Medicine, Indianapolis
| | | | - Charlotte A. Gaydos
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
| |
Collapse
|